Nicolo

Hi Mary

Thanks for your reply.

I understand that stents and PTBDs can be a higher risk for lymphodepletion phase of ACT treatment. What I don’t understand is why the stents or PTBDs is not an absolute rejection criteria for that trial, if they don’t even need to see the patient in person only with that reason. They don’t list this as rejection criteria in trial description and the study manager said it it not an absolute contraindication. That means that some patients with stents or PTBDs can be accepted to that trial. Doesn’t it? If it’s true then the rejection of my father can’t be understood. I just said he has stents and PTBDs and the bilirubin level is kept normal and that’s all. There were no submission of clinical records or other information.

We didn’t run NGS but tried to apply a few gene-based trials. FGFR I/II, IDH I/II, PD-L1 all were negative and MSI-L. Not just for the gene matching failure, in my opinion, ACT is the most promising one that can lead to a complete cure.

Thank you.

Nicolo